Abstract: Phenotypes of apolipoprotein E (apoE) were determined with an isoelectric focusing method in 39 patients with sporadic Alzheimer's disease (AD), 3 8 patients with dementia from cerebrovascular disease (CVD), and 100 healthy subjects without hyperlipidemia. There was a striking difference in the distribution of apoE phenotypes between patients with AD and healthy subjects (p<0.001) . Such a difference was attributable to different frequencies of phenotype E4/3 and E3/3. The apoE4/ 3 phenotype was detected in 38.5% (15 of 39) patients with AD, more than 3 times higher than in healthy subjects (12.0%, 12 of 100). In contrast, apoE3 / 3 phenotype, a wild type apoE phenotype, was detected in 81.0% (81 of 100) of healthy subjects but only in 38.5% (15 of 39) of patients with AD. The frequency of apoE-E4 allele assessed on the basis of obtained apoE phenotypes in patients with AD (0.269) was significantly higher than that in healthy subjects (0.08, p<0.001) and in patients with dementia from CVD (0.118, p<0.01).
2) Kurokawa Hospital .
3) Department of Neurology, Showa University School of Medicine. Alzheimer's disease (AD) is by far the most common cause of dementia. Accumulation of large senile plaques and neurofibrillary tangles is a characteristic neuropathologic manifestation of AD. Recent investigations have revealed that apolipoprotein E (apoE) is present in these structures'8 and that one particular allele, apoE-e4, is frequently associated with late-onset familial AD and sporadic AD9-11).
In the present study, we describe the association of the most common apoE phenotypes and alleles with AD. di-p-toluidine and nitroblue tetrazolium in 50 ml of stock buffer.
Statistical analysis
We estimated allele frequencies in healthy subjects and patients with dementia by counting alleles and calculating sample proportions.
Differences in the frequencies of apoE phenotypes and alleles between groups were evaluated with the XI test.
Results

ApoE phenotyping by IEF
The illustration of model patterns of apoE phenotypes and the demonstration of samples are shown in Fig. 1 . Each of the six most common phenotypes could be easily distinguished. On a gel with control samples, the three bands of apoE 3/3 homozygotes were most obvious because of the high frequency of this phenotype. The three bands of the E2/2 homozygotes were focused at distinct pI (towards the cathode), unlike the E3 bands. There were three E4 bands, but the two E4 bands on the anode side were not recognizable as separate from those of E3; thus, the E4/3 heterozygote had three bands of E3 and one band of E4. The E3/2 heterozygote had six bands, three from E3 and three from E2. The E4/4 homozygote could be distinguished from E4/3 easily, because it had only three bands and the two E4 bands were focused slightly closer to the anode side than was the E3 band. The E4/2 heterozygote had the three bands of E2 as well as the major band of E4. subjects and patients with cerebrovascular dementia (Table 2 and Fig. 2 ). On the other hand, there was a striking difference in the distribution of apoE phenotypes between patients with AD and healthy subjects (p<0.001) . Such differences were mostly attributable to differing frequencies of phenotypes E4/3 and E3/3. In patients with AD, the prevalence of E4/3 phenotype (0.385) was almost three times higher than in healthy control subjects (0.120). In contrast, the prevalence of E3/ 3 in patients with AD (0.385) was less than half of that in healthy subjects (0.810). Phenotype E4/4 was detected in two healthy subjects and one AD patient.
A poE alleles assessed from apoE phenotypes
Frequencies of apoE alleles can be assessed on the basis of obtained phenotyping data, assuming there is little discrepancy between the phenotype and genotype of apoE. The frequency of apoE-e4 allele in AD was estimated to be 0.269, which was markedly higher than those in healthy subjects (0.080; p<0.001) and patients with cerebrovascular dementia (0.118; p <0.01; Figs. 3 and 4) . The frequency of apoE-r 4 in AD patients younger than 70 years was 0.333, which was significantly higher than that of patients older than 70 Fig. 3 . Frequency of apoE alleles in Alzheimer's disease (AD), dementia from cerebra vascular disease (CVD), and healthy volunteers (HV). ApoE alleles were calculated from the phenotypes of apoE detected on electrophoresis. years ( Figure 5 ). We have two methods for detecting E4 allele: genotyping with polymerase chain reaction (PCR) 15) and phenotyping with electrophoresis16.17). Because the polymerase chain reaction method is complicated and time consuming, we used the electrophoresis method for detecting E4 allele. Electrophoresis can be used to analyze many samples at once; the commercial kit can analyze 25 samples simultaneously. We could determine the phenotype of apoE in almost all samples by the pattern of electrophoresis; however the phenotype of apoE was difficult to determine in several samples because the pattern of bands differed from the regular patterns. The frequencies of apoE phenotypes in both AD patients and healthy subjects were similar to those reported by Ueki et al.17) The frequencies of apoE phenotypes in patients with cerebrovascular dementia were a little different from those in healthy subjects. In Japan, some case of cerebrovascular dementia have characteristics of Alzheimer's disease, mixed type. We have to follow up patients carefully if they have E4 allele.
The frequency of the t4 allele in AD patients (0.269) was significantly higher than healthy subjects (0.08). Our results indicate that the E4 allele is increased in frequency in sporadic AD. The e4 frequency was 0.190 in our sporadic AD patients older than 70 years at onset and was 0.333 in patients younger than 70 years, indicating that the risk of AD associated with e4 is age-dependent and that AD develops of AD in persons with the e4 allele at an earlier age18.
Of our healthy subjects, two, aged 64 and 70 years, had apoE4/4.
They have no findings of dementia at present. If we can follow up these two cases and are able to confirm the onset of AD in the future, the significance of e4 as a risk factor for AD will be more clear.
